MA52361A - Conjugués peptidiques cycliques tyrosine-tyrosine couplés à un peptide de fusion du peptide 1 apparenté au glucagon (glp-1) et utilisations associées - Google Patents
Conjugués peptidiques cycliques tyrosine-tyrosine couplés à un peptide de fusion du peptide 1 apparenté au glucagon (glp-1) et utilisations associéesInfo
- Publication number
- MA52361A MA52361A MA052361A MA52361A MA52361A MA 52361 A MA52361 A MA 52361A MA 052361 A MA052361 A MA 052361A MA 52361 A MA52361 A MA 52361A MA 52361 A MA52361 A MA 52361A
- Authority
- MA
- Morocco
- Prior art keywords
- peptide
- tyrosine
- glp
- glucagon
- cyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862662313P | 2018-04-25 | 2018-04-25 | |
US2018029284 | 2018-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA52361A true MA52361A (fr) | 2021-03-03 |
Family
ID=66676857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052361A MA52361A (fr) | 2018-04-25 | 2019-04-24 | Conjugués peptidiques cycliques tyrosine-tyrosine couplés à un peptide de fusion du peptide 1 apparenté au glucagon (glp-1) et utilisations associées |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP3784692A1 (fr) |
JP (1) | JP2021522258A (fr) |
KR (1) | KR20210005674A (fr) |
CN (1) | CN112004822A (fr) |
AU (2) | AU2019259790B2 (fr) |
BR (1) | BR112020021562A2 (fr) |
CA (1) | CA3096792A1 (fr) |
CL (1) | CL2020002718A1 (fr) |
CO (1) | CO2020013221A2 (fr) |
CR (1) | CR20200487A (fr) |
DO (1) | DOP2020000192A (fr) |
EC (1) | ECSP20067968A (fr) |
IL (1) | IL278197A (fr) |
JO (1) | JOP20200265A1 (fr) |
MA (1) | MA52361A (fr) |
MX (1) | MX2020011293A (fr) |
NI (1) | NI202000071A (fr) |
PE (1) | PE20211457A1 (fr) |
PH (1) | PH12020551659A1 (fr) |
SA (1) | SA520420401B1 (fr) |
SG (1) | SG11202009844SA (fr) |
UY (1) | UY38200A (fr) |
WO (1) | WO2019207505A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190097A1 (ar) * | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | الجلوبولينات المناعية واستخداماتها |
CA3241537A1 (fr) * | 2021-12-31 | 2023-07-06 | Jiangyu YAN | Proteine de fusion de glp-1 et de gdf15 et son utilisation |
US20240091318A1 (en) | 2022-08-18 | 2024-03-21 | Boehringer Ingelheim International Gmbh | Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists |
CN117327200B (zh) * | 2023-11-28 | 2024-02-09 | 西宝生物科技(上海)股份有限公司 | 一种调控糖脂代谢和抗衰老的双功能重组蛋白gik及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1961000B (zh) * | 2004-02-11 | 2011-05-04 | 安米林药品公司 | 具有可选择特性的杂合多肽 |
WO2005089789A2 (fr) * | 2004-03-17 | 2005-09-29 | 7Tm Pharma A/S | Agonistes selectifs du recepteur y2 utilises dans des interventions therapeutiques |
KR20070094909A (ko) * | 2004-12-02 | 2007-09-27 | 도만티스 리미티드 | 혈청 알부민 및 glp-1 또는 pyy를 표적으로 삼는이중특이성 도메인을 갖는 항체 |
US20090175795A1 (en) * | 2005-07-29 | 2009-07-09 | Amprotein Corporation | Chimeric therapeutic agents |
MX2008002028A (es) * | 2005-08-11 | 2008-03-27 | Amylin Pharmaceuticals Inc | Polipeptidos hibridos con propiedades de seleccion. |
JP5399244B2 (ja) * | 2006-08-17 | 2014-01-29 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー | 選択可能な特性を持つdpp−iv耐性gipハイブリッドポリペプチド |
US8299023B2 (en) * | 2008-09-17 | 2012-10-30 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists |
CN102666586A (zh) * | 2009-09-30 | 2012-09-12 | 葛兰素集团有限公司 | 具有延长的半衰期的药物融合体和缀合物 |
CA3003465A1 (fr) * | 2015-10-28 | 2017-05-04 | Krishna Kumar | Nouveaux polypeptides presentant une meilleure stabilite et procedes de preparation et d'utilisation associes |
JOP20190097A1 (ar) * | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | الجلوبولينات المناعية واستخداماتها |
-
2019
- 2019-04-24 MX MX2020011293A patent/MX2020011293A/es unknown
- 2019-04-24 EP EP19727508.4A patent/EP3784692A1/fr active Pending
- 2019-04-24 CN CN201980028055.4A patent/CN112004822A/zh active Pending
- 2019-04-24 JO JOP/2020/0265A patent/JOP20200265A1/ar unknown
- 2019-04-24 WO PCT/IB2019/053384 patent/WO2019207505A1/fr active Application Filing
- 2019-04-24 CA CA3096792A patent/CA3096792A1/fr active Pending
- 2019-04-24 BR BR112020021562-7A patent/BR112020021562A2/pt unknown
- 2019-04-24 MA MA052361A patent/MA52361A/fr unknown
- 2019-04-24 SG SG11202009844SA patent/SG11202009844SA/en unknown
- 2019-04-24 JP JP2020559562A patent/JP2021522258A/ja active Pending
- 2019-04-24 KR KR1020207033769A patent/KR20210005674A/ko not_active Application Discontinuation
- 2019-04-24 PE PE2020001671A patent/PE20211457A1/es unknown
- 2019-04-24 AU AU2019259790A patent/AU2019259790B2/en active Active
- 2019-04-24 CR CR20200487A patent/CR20200487A/es unknown
- 2019-04-25 UY UY38200A patent/UY38200A/es unknown
-
2020
- 2020-10-04 PH PH12020551659A patent/PH12020551659A1/en unknown
- 2020-10-20 CL CL2020002718A patent/CL2020002718A1/es unknown
- 2020-10-21 IL IL278197A patent/IL278197A/en unknown
- 2020-10-22 SA SA520420401A patent/SA520420401B1/ar unknown
- 2020-10-22 CO CONC2020/0013221A patent/CO2020013221A2/es unknown
- 2020-10-22 NI NI202000071A patent/NI202000071A/es unknown
- 2020-10-23 DO DO2020000192A patent/DOP2020000192A/es unknown
- 2020-10-23 EC ECSENADI202067968A patent/ECSP20067968A/es unknown
-
2023
- 2023-11-29 AU AU2023274117A patent/AU2023274117A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2019259790B2 (en) | 2023-08-31 |
SG11202009844SA (en) | 2020-11-27 |
PH12020551659A1 (en) | 2021-07-26 |
UY38200A (es) | 2019-10-31 |
TW202014433A (zh) | 2020-04-16 |
JP2021522258A (ja) | 2021-08-30 |
SA520420401B1 (ar) | 2023-01-26 |
CN112004822A (zh) | 2020-11-27 |
BR112020021562A2 (pt) | 2021-03-02 |
MX2020011293A (es) | 2020-11-13 |
ECSP20067968A (es) | 2020-11-30 |
CA3096792A1 (fr) | 2019-10-31 |
CL2020002718A1 (es) | 2021-01-29 |
WO2019207505A1 (fr) | 2019-10-31 |
PE20211457A1 (es) | 2021-08-05 |
KR20210005674A (ko) | 2021-01-14 |
EP3784692A1 (fr) | 2021-03-03 |
CR20200487A (es) | 2021-03-11 |
AU2019259790A1 (en) | 2020-10-22 |
JOP20200265A1 (ar) | 2020-10-21 |
IL278197A (en) | 2020-11-30 |
AU2023274117A1 (en) | 2023-12-21 |
DOP2020000192A (es) | 2021-04-30 |
CO2020013221A2 (es) | 2020-11-10 |
NI202000071A (es) | 2021-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52361A (fr) | Conjugués peptidiques cycliques tyrosine-tyrosine couplés à un peptide de fusion du peptide 1 apparenté au glucagon (glp-1) et utilisations associées | |
DK3806855T5 (da) | GLP-1-receptoragonister og anvendelser deraf | |
DK3806955T3 (da) | GLP-1-receptoragonister og anvendelser deraf | |
AU2019410856B2 (en) | Reality capture with a laser scanner and a camera | |
FR3053530B1 (fr) | Dispositif optoelectronique a pixels a contraste et luminance ameliores | |
DK3849614T3 (da) | Interleukin-2-polypeptidkonjugater og anvendelser deraf | |
DK3505914T3 (da) | Billedsensorstruktur, fremgangsmåde til dannelse af en sådan billedsensorstruktur og anvendelse af en sådan billedsensorstruktur i et biologisk assay | |
DK3446613T3 (da) | Moppespand til rengøring og vridning af en flad moppe | |
DK3720279T3 (da) | Mus med et modificeret immunoglobulin-Lambda-letkæde og anvendelser deraf | |
EP3190782A3 (fr) | Caméra d'action | |
MA55069A (fr) | Nouvelles protéines de fusion spécifique à cd137 et gpc3 | |
FR2889969B1 (fr) | Simulateur de chutes libres apte a presenter un environnement visuel simule | |
MA53809A (fr) | Composés bifonctionnels comprenant des peptides d'insuline et des peptides d'egf(a) | |
DK3574150T3 (da) | Samling, der omfatter et første og et andet afsnit og en fiksering | |
MA50474A (fr) | Co-agonistes à action prolongée des récepteurs du glucagon et du glp-1 | |
MA51748A (fr) | Dispositif de detection tactile avec interface tactile en materiau composite | |
DK3790548T3 (da) | Fremgangsmåder til forbedring af biotilgængeligheden og eksponeringen af en åbner af spændingsstyret kaliumkanal | |
SG11202012074VA (en) | Antibodies comprising a polypeptide inserted in framework 3 region | |
MA47598A (fr) | Vitrage a contrainte d'extension reduite | |
MA54811A (fr) | Ensembles vitres feuilletées à élément fonctionnel électro-optique | |
DK3519635T3 (da) | Pæleføring omfattende en basisramme og et føringselement | |
EP3979341A4 (fr) | Élément électroluminescent ayant une électrode en porte-à-faux, panneau d'affichage le comprenant, et dispositif d'affichage | |
DK3530868T3 (da) | Endestykke til en kantskinne på en solskærm og solsejl | |
TWI847981B (zh) | 類升糖素肽1 (glp-1)融合肽偶合環狀酪酪肽接合物及其用途 | |
FR3034304A1 (fr) | Bracelet hemostatique |